prostate cancer
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Histologically proven prostate cancer • Radiologically proven limited metastatic disease • Referred to the Erasmus MC, after multidisciplinary consensus, for local radiotherapy treatment, similar to the STAMPEDE trial • Willing to and capable of personally filling out online questionnaire • Signed written informed consent
Exclusion criteria
Exclusion criteria: • Previous pelvic radiotherapy or surgery for prostate cancer (excluding surgery to improve urinary function in benign prostate hyperplasia, i.e. trans-urethral resection of the prostate or prostatectomy according to Millin or Hryntschak). • According to current clinical protocols, at discretion of the treating physician, patients can be excluded in case of, for example, an IPSS score of >20 or a prostate volume of >90ml, expecting an unacceptable rise in toxicity • Bilateral hip-replacement surgery, which compromises the visibility of the target area on the in-room CT-scan
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main endpoint: Percentage of patients for which in 0 or 1 out 6 fractions the SV were underdosed. Underdosage being defined as 95% of the volume of SV receiving =90% of patients received successful treatments. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: Quantify and assess toxicity using questionnaires. Quantify and assess target coverage and OAR dose when only the prostate is targeted. | — |
Countries
Netherlands
Outcome results
None listed